Medical Oncology: Second-line XELOX or FOLFOX-4 for metastatic colorectal cancer
- PMID: 19390547
- DOI: 10.1038/nrclinonc.2009.46
Medical Oncology: Second-line XELOX or FOLFOX-4 for metastatic colorectal cancer
Abstract
In the movement towards individualized treatment regimens, Rothenberg et al. validate XELOX as another available systemic therapy for patients being treated with second-line treatment for metastatic colorectal cancer. This paper adds to a growing body of data in the first-line and second-line setting that confirms the noninferiority of oral fluoropyrimidine-containing regimens.
Comment on
-
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.Ann Oncol. 2008 Oct;19(10):1720-6. doi: 10.1093/annonc/mdn370. Epub 2008 Jun 10. Ann Oncol. 2008. PMID: 18550577 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
